Managed Care

A Phase II Trial Finds Ixekizumab “Extremely Effective” and Safe for Psoriasis

Kenneth Gordon, Professor of Dermatology at Northwestern University, discusses phase II safety and efficacy studies of the anti–interleukin-17 monoclonal antibody ixekizumab for psoriasis. In a year-long extension of a 12-week trial, ixekizumab was “extremely effective” at sustaining responses, leading to complete clearance in 40% to 50% of patients. The drug was also very well tolerated, with no safety signals that raised concern.


Medical Devices Summit Boston, MA February 19–20, 2015
3rd Annual Summit to Improve Adherence and Enhance Patient Engagement Philadelphia, PA March 9–10, 2015
Value-Added Solutions for Enhanced Customer Experience Philadelphia, PA March 9, 2015